HASBROUCK HEIGHTS, N.J., Nov. 22, 2011 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX - News) provided an update today on the Company’s Phase 3 pivotal trials for NX-1207, Nymox’s investigational drug for benign prostatic hyperplasia (BPH). The Safety Monitoring Committee meeting of November 15, 2011 was favorable and indicated no significant safety concerns for the two pivotal U.S. trials to date. Patient recruitment and trial activities for pivotal U.S. studies NX02-0017 and NX02-0018 are ongoing at over 80 well-known urology investigative sites throughout the U.S. Accrual numbers for Trial NX02-0017 have reached approximately 80%, and steady progress has been made toward full enrollment for the pivotal studies.
